| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Bourla Albert, Director
Granted 21 Phantom Stock Units SSP ($607) |
| 12 Nov 2026 | 13F-HR |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience |
| 03 Nov 2026 |
Form 4: Bourla Albert, Director
Granted 20 Phantom Stock Units SSP ($610) |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
■Focused Execution Drove 32% Operational Revenue Growth of Launched and Acquired Products(1) |
| 16 Oct 2026 |
Form 4: Bourla Albert, Director
Granted 20 Phantom Stock Units SSP ($589) |
| 16 Oct 2026 | SCHEDULE 13G |
| 14 Oct 2026 |
Form 4: Bourla Albert, Director
Granted 71 Phantom Stock Units SSP ($2.01K) |
| 01 Oct 2026 |
Form 4: Bourla Albert, Director
Granted 21 Phantom Stock Units SSP ($599) |
| 29 Sep 2026 |
Form 4: Buckley Mortimer J, Director
Granted 1,307.987 Phantom Stock Units ($37.5K) |
| 29 Sep 2026 |
Form 4: Echevarria Joseph, Director
Granted 1,613.185 Phantom Stock Units ($46.3K) |
| 29 Sep 2026 |
Form 4: Narayen Shantanu, Director
Granted 1,743.983 Phantom Stock Units ($50K) |
| 29 Sep 2026 |
Form 4: Quincey James, Director
Granted 1,351.587 Phantom Stock Units ($38.7K) |
| 29 Sep 2026 |
Form 4: Smith James C, Director
Granted 1,569.585 Phantom Stock Units ($45K) |
| 29 Sep 2026 |
Form 4: Taraporevala Cyrus, Director
Granted 1,307.987 Phantom Stock Units ($37.5K) |
| 16 Sep 2026 |
Form 4: Bourla Albert, Director
Granted 22 Phantom Stock Units SSP ($606) |
| 01 Sep 2026 |
Form 4: Bourla Albert, Director
Granted 21 Phantom Stock Units SSP ($598) |
| 31 Aug 2026 | N-PX |
| 28 Aug 2026 |
Form 3: Guegan Cecile, Executive Vice President
Holds 149,505 shares of Common Stock |
Loading...